CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy

Annals of Oncology

Volumn 19, Issue 11, 2008, Pages 1921-1926

  Ennishi, D ^a,c   Takeuchi, K ^b   Yokoyama, M ^a   Asai, H ^a   Mishima, Y ^a   Terui, Y ^a   Takahashi, S ^a   Komatsu, H ^c   Ikeda, K ^c   Yamaguchi, M ^d   Suzuki, R ^e   Tanimoto, M ^c   Hatake, K ^a  

^a CANCER INSTITUTE HOSPITAL   (Japan)

^b CANCER CHEMOTHERAPY CENTER   (Japan)

^c OKAYAMA UNIVERSITY   (Japan)

^d MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Biomarker; CD5; Diffuse large B cell lymphoma; Rituximab

Indexed keywords

BIOLOGICAL MARKER; CD5 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; PROTEIN BCL 2; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; CANCER STAGING; DISEASE FREE SURVIVAL; FEMALE; GERMINAL CENTER; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; RETROSPECTIVE STUDY;

EID: 54949091570     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn392     Document Type: Article

References (30)

1. Jaffe ES, Harris NL, Stein H, Vardiman JW. (eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissue. 2001.
2. Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002-1006.
3. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
4. Pfreundschuh M, Trumper L, Osterborg A et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-391.
5. Sehn LH, Donaldson J, Chhanabhai M et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005; 23: 5027-5033.
6. TIN-HsLPF P. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987-994.
7. Yunis JJ, Mayer MG, Arnesen MA et al. bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. N Engl J Med 1989; 320: 1047-1054.
8. Kramer MH, Hermans J, Wijburg E et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 1998; 92: 3152-3162.
9. Lossos IS, Jones CD, Wamke R et al. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood 2001; 98: 945-951.
10. Yamaguchi M, Ohno T, Oka K et al. De novo CD5-positive diffuse large B-cell lymphoma: Clinical characteristics and therapeutic outcome. Br J Haematol 1999; 105: 1133-1139.
11. Yamaguchi M, Seto M, Okamoto M et al. De novo CD5+ diffuse large B-cell lymphoma: A clinicopathologic study of 109 patients. Blood 2002; 99: 815-821.
12. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511.
13. Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-282.
14. Sehn LH, Berry B, Chhanabhai M et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007; 109: 1857-1861.
15. Mounier N, Briere J, Gisselbrecht C et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003; 101: 4279-4284.
16. Winter JN, Weller EA, Horning SJ et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: A prospective correlative study. Blood 2006; 107: 4207-4213.
17. Nyman H, Adde M, Kadalainen-Lindsberg ML et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2007; 109: 4930-4935.
18. Ogura M, Morishima Y, Kagami Y et al. Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma. Cancer Sci 2006; 97: 305-312.
19. Linderoth J, Jerkeman M, Cavallin-Stahl E et al. Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: A Nordic Lymphoma Group Study. Clin Cancer Res 2003; 9: 722-728.
20. Randy D, Gascoyne SD, Zetti Andreas et al. Gene expression microarray analysis of de novo CD5+ diffuse large b-cell lymphoma (LLMPP study): A distinct Entity? Blood 2003; 102: 178a.
21. Marshall A, Lichtman EB, Thomas J Kipps et al. Prchal Part VIII. Lymphocytes and Plasma Cells. Williams Hematology 7th edition 2006.
22. Kaufmann O, Flath B, Spath-Schwalbe E et al. Immunohistochemical detection of CD5 with monoclonal antibody 4C7 on paraffin sections. Am J Clin Pathol 1997; 108: 669-673.
23. Dorfman DM, Shahsafaei A. Usefulness of a new CD5 antibody for the diagnosis of T-cell and B-cell lymphoproliferative disorders in paraffin sections. Mod Pathol 1997; 10: 859-863.
24. de Jong D, Rosenwald A, Chhanabhai M et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: Validation of tissue microarray as a prerequisite for broad clinical applications - a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 2007; 25: 805-812.
25. Kobayashi T, Yamaguchi M, Kim S et al. Microarray reveals differences in both tumors and vascular specific gene expression in de novo CD5+ and CD5- diffuse large B-cell lymphomas. Cancer Res 2003; 63: 60-66.
26. Kaman S, Tagawa H, Suzuki R et al. Analysis of chromosomal imbalances in de novo CD5-positive diffuse large-B-cell lymphoma detected by comparative genomic hybridization. Genes Chromosomes Cancer 2004; 39: 77-81.
27. Tagawa H, Suguro M, Tsuzuki S et al. Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. Blood 2005; 106: 1770-1777.
28. Kume M, Suzuki R, Yatabe Y et al. Somatic hypermutations in the VH segment of immunoglobulin genes of CD5-positive diffuse large B-cell lymphomas. Jpn J Cancer Res 1997; 88: 1087-1093.
29. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001; 194: 1861-1874.
30. Choi W WD, Greiner T, Piris M et al. A new immustain improves the classification of diffuse large B-cell lymphoma into prognostically significant subgroups. Mod Pathol 2008; 21: 250A.